Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Itonis Pharmaceuticals announces first Emesyl manufacturer production release date
The actual manufacturing of the company’s Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to
The actual manufacturing of the company’s Emesyl® product is on schedule to begin August 18, 2014. We are pleased to be able to make these dates available to
The white blood cells that produce these antibodies assemble their specific versions by selecting three gene segments from among multiple variants. Joseph Lucas, a graduate student working with
The labeling update includes dosing guidelines as well as safety and efficacy findings for the use of VELCADE as a single agent or VELCADE in combination with dexamethasone
Data Highlights BIOD-531 was associated with superior glucose control compared to Humalog Mix 75/25 throughout the day of observation. BIOD-531 was also associated with superior glucose control compared
Mosquitos can easily and efficiently transmit this virus to humans causing high fever, severe muscle/joint pain, headache, fatigue and rash. While there is currently no FDA-approved vaccine to
The administration of particulate matter, if present in an intravenous drug, poses a potential safety risk to patients such as a thromboembolism or a life-threatening pulmonary embolism. Other
Under the agreement, Fred’s and Cardinal Health will establish a mutually beneficial strategic alliance designed to support Fred’s key initiative of rapid pharmacy growth, and build on a
This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza’s commercial partner for ADASUVE in the EU, Latin America and Commonwealth
The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed
The patent describes and claims a targeted drug delivery method that combines bacterial minicells and a "bispecific ligand" in a composition lacking undesirable contamination from parent bacterial cells